Journal article
Suberanilohydroxamic acid aton pharma
RW Johnstone
IDRUGS | THOMSON REUTERS (SCIENTIFIC) LTD | Published : 2004
Abstract
Aton Pharma Inc, under license from the Memorial Sloan-Kettering Cancer Center, is developing suberanilohydroxamic acid (SAHA), a cytodifferentiating agent and histone deacetylase inhibitor, as a potential cancer chemopreventive.